BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 17283122)

  • 1. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.
    Tsuda M; Davis IJ; Argani P; Shukla N; McGill GG; Nagai M; Saito T; Laé M; Fisher DE; Ladanyi M
    Cancer Res; 2007 Feb; 67(3):919-29. PubMed ID: 17283122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.
    Kobos R; Nagai M; Tsuda M; Merl MY; Saito T; Laé M; Mo Q; Olshen A; Lianoglou S; Leslie C; Ostrovnaya I; Antczak C; Djaballah H; Ladanyi M
    J Pathol; 2013 Apr; 229(5):743-754. PubMed ID: 23288701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma.
    Vistica DT; Krosky PM; Kenney S; Raffeld M; Shoemaker RH
    J Pediatr Hematol Oncol; 2008 Jan; 30(1):46-52. PubMed ID: 18176180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21.
    Ishiguro N; Yoshida H
    Neoplasia; 2016 Oct; 18(10):626-635. PubMed ID: 27673450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
    Ladanyi M; Lui MY; Antonescu CR; Krause-Boehm A; Meindl A; Argani P; Healey JH; Ueda T; Yoshikawa H; Meloni-Ehrig A; Sorensen PH; Mertens F; Mandahl N; van den Berghe H; Sciot R; Dal Cin P; Bridge J
    Oncogene; 2001 Jan; 20(1):48-57. PubMed ID: 11244503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
    Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Histogenesis and Diagnostic Strategy Using Immunoassay and RT-PCR in Alveolar Soft Part Sarcoma.
    Ju X; Sun K; Liu R; Li S; Abulajiang G; Zou H; Lan J; Ren Y; Jiang J; Liang W; Pang L; Li F
    Pathol Oncol Res; 2018 Jul; 24(3):593-600. PubMed ID: 28766250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues.
    Pang LJ; Chang B; Zou H; Qi Y; Jiang JF; Li HA; Hu WH; Chen YZ; Liu CX; Zhang WJ; Li F
    Diagn Mol Pathol; 2008 Dec; 17(4):245-52. PubMed ID: 18382356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.
    Covell DG; Wallqvist A; Kenney S; Vistica DT
    PLoS One; 2012; 7(11):e48023. PubMed ID: 23226201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed, paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: useful diagnostic tools in cases with unusual histological features.
    Williams A; Bartle G; Sumathi VP; Meis JM; Mangham DC; Grimer RJ; Kindblom LG
    Virchows Arch; 2011 Mar; 458(3):291-300. PubMed ID: 21279521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
    Argani P; Antonescu CR; Illei PB; Lui MY; Timmons CF; Newbury R; Reuter VE; Garvin AJ; Perez-Atayde AR; Fletcher JA; Beckwith JB; Bridge JA; Ladanyi M
    Am J Pathol; 2001 Jul; 159(1):179-92. PubMed ID: 11438465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of ASPL-TFE3 fusion gene by reverse transcriptase polymerase chain reaction in paraffin-embedded tumor tissues of alveolar soft part sarcoma].
    Pang LJ; Li F; Chang B; Hu WH; Lu TC; Li XX; Li HA; Jiang JF
    Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):508-12. PubMed ID: 15634444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript.
    Tsuji K; Ishikawa Y; Imamura T
    Hum Pathol; 2012 Mar; 43(3):356-63. PubMed ID: 21835426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC.
    Wang B; Gan W; Han X; Liu N; Ma T; Li D
    Int J Biol Macromol; 2021 Apr; 176():437-447. PubMed ID: 33592266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
    Vistica DT; Hollingshead M; Borgel SD; Kenney S; Stockwin LH; Raffeld M; Schrump DS; Burkett S; Stone G; Butcher DO; Shoemaker RH
    J Pediatr Hematol Oncol; 2009 Aug; 31(8):561-70. PubMed ID: 19636271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
    Argani P; Lal P; Hutchinson B; Lui MY; Reuter VE; Ladanyi M
    Am J Surg Pathol; 2003 Jun; 27(6):750-61. PubMed ID: 12766578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas.
    Aulmann S; Longerich T; Schirmacher P; Mechtersheimer G; Penzel R
    Histopathology; 2007 Jun; 50(7):881-6. PubMed ID: 17543078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
    Damayanti NP; Cordova RA; Rupert C; Delle Fontane I; Shen L; Orsi S; Klunk AJ; Linehan WM; Staschke KA; Hollenhorst PC; Heppner DE; Pili R
    Cancer Res; 2024 Apr; 84(8):1286-1302. PubMed ID: 38266162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cardiac alveolar soft part sarcoma. A report of the first observed case with molecular diagnostics corroboration.
    Luo J; Melnick S; Rossi A; Burke RP; Pfeifer JD; Dehner LP
    Pediatr Dev Pathol; 2008; 11(2):142-7. PubMed ID: 17378669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.